Pharmaceutical preparation composed of dosage unit

摘要

The use of a phosphodiesterase (PDE5) inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction in a patient either (a) being treated with an organic nitrate, (b) prone to vision abnormalities, (c) prone to flushes, (d) suffering from retinal disease, (e) suffering from class 1 congestive heart failure or (f) has suffered myocardial infarction 90 days or more before treatment with the said PDE5 inhibitor.